GFR-话题@MedSci

#GFR#

483篇内容 | 2459人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534200, encodeId=6b571534200ff, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Hypertension:eGFR预测终点数少于24小时动态血压, objectType=article, longId=11899, objectId=19fa1189903, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19fa1189903, replyNumber=0, likeNumber=54, createdTime=2012-11-30, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19fa1189903, moduleTitle=Hypertension:eGFR预测终点数少于24小时动态血压, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19fa1189903)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534199, encodeId=e9a9153419995, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JCO：化疗与EGFR突变关系, objectType=article, longId=9464, objectId=3a57946478, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a57946478, replyNumber=0, likeNumber=97, createdTime=2012-09-05, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a57946478, moduleTitle=JCO：化疗与EGFR突变关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a57946478)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534198, encodeId=9558153419884, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lung Cancer：皮疹可能预示抗EGFR治疗肺癌有效, objectType=article, longId=8411, objectId=9f7d8411fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f7d8411fc, replyNumber=0, likeNumber=0, createdTime=2012-08-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f7d8411fc, moduleTitle=Lung Cancer：皮疹可能预示抗EGFR治疗肺癌有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f7d8411fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534197, encodeId=8439153419ec7, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Science：转化性FGFR-TACC基因融合引发恶性胶质母细胞瘤, objectType=article, longId=8275, objectId=6f5a82e5e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f5a82e5e3, replyNumber=0, likeNumber=53, createdTime=2012-07-29, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f5a82e5e3, moduleTitle=Science：转化性FGFR-TACC基因融合引发恶性胶质母细胞瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f5a82e5e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534196, encodeId=98df1534196bd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=PLoS ONE：阻断FGFR抑制肿瘤转移, objectType=article, longId=7666, objectId=da37e666a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da37e666a8, replyNumber=0, likeNumber=71, createdTime=2012-07-08, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da37e666a8, moduleTitle=PLoS ONE：阻断FGFR抑制肿瘤转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da37e666a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534195, encodeId=cb8b1534195f7, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Nature：抗-EGFR疗法中的获得性抗药性, objectType=article, longId=7577, objectId=eb12e577c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb12e577c2, replyNumber=0, likeNumber=52, createdTime=2012-07-05, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb12e577c2, moduleTitle=Nature：抗-EGFR疗法中的获得性抗药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb12e577c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534194, encodeId=dbea1534194fd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=PLoS One：FGFR1诱导肿瘤上皮间质转化机制, objectType=article, longId=7534, objectId=7249e53419, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7249e53419, replyNumber=0, likeNumber=120, createdTime=2012-07-04, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7249e53419, moduleTitle=PLoS One：FGFR1诱导肿瘤上皮间质转化机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7249e53419)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534192, encodeId=bdd2153419286, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=GFR降低可能为老年LI的重要危险因素, objectType=article, longId=7506, objectId=cdc9e50652, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdc9e50652, replyNumber=0, likeNumber=80, createdTime=2012-07-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdc9e50652, moduleTitle=GFR降低可能为老年LI的重要危险因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdc9e50652)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534193, encodeId=9ddd1534193b4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=两篇Nature文章：聚焦结直肠癌抗EGFR治疗耐药, objectType=article, longId=7510, objectId=9b93e51032, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b93e51032, replyNumber=0, likeNumber=73, createdTime=2012-07-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b93e51032, moduleTitle=两篇Nature文章：聚焦结直肠癌抗EGFR治疗耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b93e51032)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534191, encodeId=11e8153419157, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Nature:解开结肠癌获得性抵抗EGFR阻断治疗之谜, objectType=article, longId=7180, objectId=e304e18050, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e304e18050, replyNumber=0, likeNumber=90, createdTime=2012-06-20, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e304e18050, moduleTitle=Nature:解开结肠癌获得性抵抗EGFR阻断治疗之谜, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e304e18050)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534190, encodeId=3eba15341903d, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=【ASCO 2012】厄洛替尼辅助治疗使EGFR突变NSCLC患者获益, objectType=article, longId=6938, objectId=f8c36938e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8c36938e2, replyNumber=0, likeNumber=90, createdTime=2012-06-11, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8c36938e2, moduleTitle=【ASCO 2012】厄洛替尼辅助治疗使EGFR突变NSCLC患者获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8c36938e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534189, encodeId=8b2f153418925, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JCI：FoxO1基因破坏EGFR信号克服肿瘤耐药, objectType=article, longId=6897, objectId=5de3689ef8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5de3689ef8, replyNumber=0, likeNumber=77, createdTime=2012-06-11, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5de3689ef8, moduleTitle=JCI：FoxO1基因破坏EGFR信号克服肿瘤耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5de3689ef8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534188, encodeId=48461534188c3, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=厄洛替尼辅助治疗可使EGFR突变NSCLC患者受益, objectType=article, longId=6887, objectId=f079688e22, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f079688e22, replyNumber=0, likeNumber=61, createdTime=2012-06-09, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f079688e22, moduleTitle=厄洛替尼辅助治疗可使EGFR突变NSCLC患者受益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f079688e22)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534187, encodeId=2cc8153418e7e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=PLoS ONE：靶向FGFR4能够抑制肝细胞癌, objectType=article, longId=6513, objectId=2c396513d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c396513d4, replyNumber=0, likeNumber=57, createdTime=2012-05-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c396513d4, moduleTitle=PLoS ONE：靶向FGFR4能够抑制肝细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c396513d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534186, encodeId=7aed153418686, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JAMA：CKD-EPI方程肝算肾小球滤过率（GFR）能更好评估肾脏疾病风险, objectType=article, longId=6387, objectId=ec0d638e5d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec0d638e5d, replyNumber=0, likeNumber=58, createdTime=2012-05-21, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec0d638e5d, moduleTitle=JAMA：CKD-EPI方程肝算肾小球滤过率（GFR）能更好评估肾脏疾病风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec0d638e5d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534185, encodeId=89151534185c7, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=EGFR可以作为NSCLC治疗靶标, objectType=article, longId=5170, objectId=a49351e034, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a49351e034, replyNumber=0, likeNumber=71, createdTime=2012-04-15, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a49351e034, moduleTitle=EGFR可以作为NSCLC治疗靶标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a49351e034)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534184, encodeId=ecc715341840c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=GFR下降与高血压患者的全因和CVD死亡相关, objectType=article, longId=4558, objectId=3aaf455863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3aaf455863, replyNumber=0, likeNumber=82, createdTime=2012-04-11, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3aaf455863, moduleTitle=GFR下降与高血压患者的全因和CVD死亡相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3aaf455863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534183, encodeId=9210153418355, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=EBM：OGF-OGFr在卵巢癌生物学中起关键作用, objectType=article, longId=4111, objectId=8e724111c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e724111c6, replyNumber=0, likeNumber=0, createdTime=2012-02-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e724111c6, moduleTitle=EBM：OGF-OGFr在卵巢癌生物学中起关键作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e724111c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534182, encodeId=94ce15341825d, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=克服肺癌EGFR-TKI耐药的新方法, objectType=article, longId=3782, objectId=d35d3e8239, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d35d3e8239, replyNumber=0, likeNumber=71, createdTime=2012-01-27, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d35d3e8239, moduleTitle=克服肺癌EGFR-TKI耐药的新方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d35d3e8239)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534181, encodeId=6ae91534181fb, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=王洁：克服EGFR-TKI耐药的新方法, objectType=article, longId=3196, objectId=e919319619, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e919319619, replyNumber=0, likeNumber=64, createdTime=2011-10-17, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e919319619, moduleTitle=王洁：克服EGFR-TKI耐药的新方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e919319619)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Hypertension:eGFR预测终点数少于24小时动态血压

2012-11-30

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JCO：化疗与EGFR突变关系

2012-09-05

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lung Cancer：皮疹可能预示抗EGFR治疗肺癌有效

2012-08-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Science：转化性FGFR-TACC基因融合引发恶性胶质母细胞瘤

2012-07-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

PLoS ONE：阻断FGFR抑制肿瘤转移

2012-07-08

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Nature：抗-EGFR疗法中的获得性抗药性

2012-07-05

liuyiping (审核中...)

前往app查看评论内容

#GFR#

PLoS One：FGFR1诱导肿瘤上皮间质转化机制

2012-07-04

liuyiping (审核中...)

前往app查看评论内容

#GFR#

GFR降低可能为老年LI的重要危险因素

2012-07-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

两篇Nature文章：聚焦结直肠癌抗EGFR治疗耐药

2012-07-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Nature:解开结肠癌获得性抵抗EGFR阻断治疗之谜

2012-06-20

liuyiping (审核中...)

前往app查看评论内容

#GFR#

【ASCO 2012】厄洛替尼辅助治疗使EGFR突变NSCLC患者获益

2012-06-11

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JCI：FoxO1基因破坏EGFR信号克服肿瘤耐药

2012-06-11

liuyiping (审核中...)

前往app查看评论内容

#GFR#

厄洛替尼辅助治疗可使EGFR突变NSCLC患者受益

2012-06-09

liuyiping (审核中...)

前往app查看评论内容

#GFR#

PLoS ONE：靶向FGFR4能够抑制肝细胞癌

2012-05-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JAMA：CKD-EPI方程肝算肾小球滤过率（GFR）能更好评估肾脏疾病风险

2012-05-21

liuyiping (审核中...)

前往app查看评论内容

#GFR#

EGFR可以作为NSCLC治疗靶标

2012-04-15

liuyiping (审核中...)

前往app查看评论内容

#GFR#

GFR下降与高血压患者的全因和CVD死亡相关

2012-04-11

liuyiping (审核中...)

前往app查看评论内容

#GFR#

EBM：OGF-OGFr在卵巢癌生物学中起关键作用

2012-02-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

克服肺癌EGFR-TKI耐药的新方法

2012-01-27

liuyiping (审核中...)

前往app查看评论内容

#GFR#

王洁：克服EGFR-TKI耐药的新方法

2011-10-17

科室
- - 订阅+
  - 更多科室
工具
服务